Novavax reports $57M Q2 revenue, advances vaccine trials, raises 2026 revenue guidance

Novavax reported $57 million in revenue for Q2 2026, down 76% from last year due to milestone timing but saw a 76% rise in product sales. The company is progressing with its Sanofi partnership, including advanced talks on a Phase 3 COVID-19-Influenza combination vaccine trial, which could trigger $125 million in milestones. Novavax also plans to enter clinical trials for a C. difficile vaccine by 2027 and is expanding its Matrix-M adjuvant collaborations. It raised its full-year 2026 revenue guidance to $235-$275 million while reducing combined R&D and SG&A expenses guidance, signaling confidence in its strategy and future growth.